As GLP-1 medications like Ozempic and Wegovy reshape the pharmaceutical landscape with blockbuster sales, a new study from the National Bureau of Economic Research tackles the question insurers and employers desperately need answered: Do these expensive drugs actually pay for themselves through reduced healthcare costs?
The NBER working paper digs into the economics behind medications that can cost $1,000 per month or more. For corporate HR departments and insurance actuaries, this isn't academic—it's a bottom-line question that affects coverage decisions for millions of Americans.
GLP-1 drugs have demonstrated remarkable effectiveness for weight loss and glycemic control, with some patients losing 15-20% of body weight. The pharmaceutical industry's pitch to payers is straightforward: Yes, the drugs are expensive upfront, but they'll save money long-term by preventing costly complications like heart disease, stroke, and diabetes-related hospitalizations.
The NBER researchers examined whether that math actually works. Their findings matter because we're talking about a market that Goldman Sachs has estimated could reach $100 billion annually by 2030. Every major insurer and self-insured employer is wrestling with whether to cover these medications broadly, restrict them to specific populations, or avoid coverage entirely.
The complicating factors are significant: medication adherence rates, the time horizon for health benefits to materialize, whether patients maintain weight loss after discontinuing the drugs, and the likelihood that healthier employees might switch insurers before the long-term savings materialize. In the world of corporate health benefits, you don't get credit for saving money on an employee who leaves for another company in three years.
From a pure financial perspective, this is a classic present-value calculation with massive uncertainty. Spend $12,000 per patient annually now, potentially save $20,000 in avoided complications over the next decade—but only if the patient stays on the medication, maintains the weight loss, and remains in your insurance pool long enough for you to capture those savings.
For Novo Nordisk and , the pharmaceutical giants behind these drugs, favorable NBER findings could unlock billions in additional coverage. For employers and insurers, the decision involves balancing immediate budget impacts against theoretical long-term savings that may or may not materialize.
